epz-6438 and dabrafenib

epz-6438 has been researched along with dabrafenib* in 1 studies

Other Studies

1 other study(ies) available for epz-6438 and dabrafenib

Article	Year
Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:6 Clinical efficacy of differentiation therapy with mitogen-activated protein kinase inhibitors (MAPKi) for lethal radioiodine-refractory papillary thyroid cancer (RR-PTC) urgently needs to be improved and the aberrant trimethylation of histone H3 lysine 27 (H3K27) plays a vital role in BRAF Topics: Benzamides; Benzimidazoles; Biphenyl Compounds; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Histones; Humans; Imidazoles; Iodine Radioisotopes; Methylation; Mitogen-Activated Protein Kinases; Morpholines; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Thyroid Cancer, Papillary; Thyroid Gland	2020

Article

Year

Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF

Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:6

Clinical efficacy of differentiation therapy with mitogen-activated protein kinase inhibitors (MAPKi) for lethal radioiodine-refractory papillary thyroid cancer (RR-PTC) urgently needs to be improved and the aberrant trimethylation of histone H3 lysine 27 (H3K27) plays a vital role in BRAF

Topics: Benzamides; Benzimidazoles; Biphenyl Compounds; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Histones; Humans; Imidazoles; Iodine Radioisotopes; Methylation; Mitogen-Activated Protein Kinases; Morpholines; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Thyroid Cancer, Papillary; Thyroid Gland

2020